Amicus Splits into Two as FDA Sets PDUFA for Pompe Disease Treatment

Amicus Splits into Two as FDA Sets PDUFA for Pompe Disease Treatment

Source: 
BioSpace
snippet: 

Amicus Therapeutics is launching a next-generation genetic medicine company called Caritas Therapeutics, Inc. through a merger deal with ARYA Sciences Acquisition Corp IV, a special purpose acquisition company sponsored by Perceptive Advisors.